bendamustine

P1, N=20, Completed, Noah Merin | Active, not recruiting --> Completed | N=30 --> 20 | Trial completion date: Nov 2031 --> Nov 2024

P1, N=9, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=15 --> 9

A 75-year-old man presented with uveitis masquerade syndrome while undergoing treatment for MCL with rituximab-bendamustine. During the study course, CD5 and CD20 positive cells were identified in the anterior chamber of the eyes via flow cytometry, which was consistent with the pathological findings of biopsies. Ibrutinib may improve recurrent MCL intraocular lesions.

Patients who received bendamustine required more platelet transfusions (p = 0.02)...Conditioning with BEAM and BeEAM regimens is associated with comparable post-transplant outcomes. The toxicity of these regimens is comparable; however, BEAM is associated with a higher risk of pneumonia, while BeEAM is associated with a higher risk of mucositis.

P1, N=12, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

P1, N=25, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2025

P2, N=50, Completed, St. Petersburg State Pavlov Medical University | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024 | Trial primary completion date: Dec 2023 --> May 2024

However, bendamustine + rituximab had a more favorable safety profile for grade ⩾3 AEs when compared with ibrutinib (risk ratio 0.62 (95% credible interval 0.40-0.86)), acalabrutinib (0.69 (0.45-0.94)), zanubrutinib (0.64 (0.42-0.91)), and venetoclax + rituximab (0.87 (0.79-0.96)). Our findings showed that venetoclax + rituximab, acalabrutinib, and zanubrutinib have acceptable safety profiles, which indicates that they may be the preferred therapeutic options in the setting of relapsed/refractory CLL. PROSPERO CRD42022304330.

P2, N=24, Not yet recruiting, Fox Chase Cancer Center | Initiation date: Sep 2024 --> Dec 2024

P3, N=86, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Jun 2024 --> Dec 2024

P3, N=1030, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed

P3, N=1080, Recruiting, Genmab | Trial primary completion date: Jan 2030 --> May 2037

In this study, we have shown the cytotoxicity of BDM alone and in combination with novel agents including the histone deacetylase (HDAC) inhibitor tucidinostat, the enhancer of zeste homolog 1/2 (EZH1/2) dual inhibitor valemetostat, and the Bcl2 family inhibitor ABT-737. Our present results suggest that the combination of tucidinostat and BDM could additively prolong the survival of patients with R/R progressive ATL. The efficacy and safety of this combination are thus worthy of investigation in clinical settings.

Our results encourage the pursuit of clinical trials of combined treatment with NL101 and venetoclax and provide a novel venetoclax-incorporating therapeutic strategy for AML.

P1/2, N=170, Active, not recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Dec 2024

The patient received bendamustine and rituximab as chemotherapy, which rapidly improved the anemia and splenomegaly and reduced atypical lymphocytes. An autopsy revealed that the tumor had invaded several organs including the pancreas, and immunohistochemistry was positive for CD163, leading to the diagnosis of HS. Furthermore, the specimens of SMZL and HS were positive for IgH gene reconstitution, and exome analysis showed genetic abnormalities in 226 genes including CARD11, suggesting that the SMZL and HS had the same origin.

P2, N=33, Completed, PrECOG, LLC. | Trial completion date: Nov 2024 --> Jul 2024 | Active, not recruiting --> Completed

P2, N=42, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | N=30 --> 42

P3, N=523, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed

P2, N=49, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Feb 2027 --> Apr 2029 | Trial primary completion date: Feb 2025 --> Apr 2026

P2, N=100, Not yet recruiting, Chinese PLA General Hospital

P2, N=37, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024

P2, N=55, Not yet recruiting, Massachusetts General Hospital

Here, we demonstrated the antileukemia activity of a novel small molecular compound NL101, which is formed through the modification on bendamustine with a suberanilohydroxamic acid (SAHA) radical. The inhibition of mammalian target of rapamycin (mTOR) by rapamycin enhanced the sensitivity of AML cells to NL101-induced cell death. These findings uncover PTEN protein expression as a major determinant of chemosensitivity to NL101 and provide a novel strategy to treat AML with the combination of NL101 and rapamycin.

P2, N=24, Not yet recruiting, Fox Chase Cancer Center

P2, N=36, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P=N/A, N=100, Recruiting, Uppsala University | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Aug 2024

P1, N=64, Recruiting, Fate Therapeutics | N=32 --> 64

P3, N=1080, Recruiting, Genmab | Trial primary completion date: May 2037 --> Jan 2030

P2, N=90, Recruiting, Celgene | Not yet recruiting --> Recruiting

P2, N=88, Recruiting, St. Petersburg State Pavlov Medical University

When camidanlumab tesirine-containing combinations were evaluated in four T-cell lymphoma models, the most active partners were everolimus, copanlisib, venetoclax, vorinostat, and pralatrexate, followed by bortezomib, romidepsin, bendamustine, and 5-azacytidine. The strong camidanlumab tesirine single-agent anti-lymphoma activity and the in vitro synergisms with targeted agents identify potential combination partners for future clinical studies.

P=N/A, N=58, Completed, Rehab Werida | Trial primary completion date: Sep 2023 --> Dec 2023

P1/2, N=122, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Dec 2028 --> Apr 2030 | Trial primary completion date: May 2025 --> Apr 2027

P3, N=124, Not yet recruiting, SecuraBio

P1, N=166, Recruiting, Fate Therapeutics | N=322 --> 166

P2, N=168, Active, not recruiting, Miltenyi Biomedicine GmbH | Recruiting --> Active, not recruiting

P2, N=6, Terminated, Wake Forest University Health Sciences | N=12 --> 6 | Trial completion date: Jun 2025 --> Jul 2024 | Recruiting --> Terminated; Low accruals

A 71-year-old woman was diagnosed with asymptomatic MLP during MCL staging who underwent thoracentesis due to large right pleural effusion and significant axillary lymphadenopathy and was treated with a chemotherapy regimen of rituximab/cytarabine and later transitioned to bendamustine/rituximab. This patient eventually underwent a bone marrow biopsy and later a bone marrow transplant. We present a unique case of asymptomatic MLP, emphasizing the importance of early detection for the poor prognosis of MLP with a mean survival of less than 3 years.

P2/3, N=450, Completed, MorphoSys AG | Active, not recruiting --> Completed

P2, N=73, Recruiting, First Affiliated Hospital of Zhejiang University

P3, N=78, Recruiting, Ruijin Hospital